2.50
Hdl Handle:
http://hdl.handle.net/10033/316733
Title:
Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.
Authors:
Mullen, Lisa; Rigby, Anne; Sclanders, Michelle; Adams, Gill; Mittal, Gayatri; Colston, Julia; Fatah, Rewas; Subang, Cristina; Foster, Julie; Francis-West, Philippa; Köster, Mario; Hauser, Hansjörg; Layward, Lorna; Vessillier, Sandrine; Annenkov, Alex; Al-Izki, Sarah; Pryce, Gareth; Bolton, Chris; Baker, David; Gould, David J; Chernajovsky, Yuti
Abstract:
Targeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes.
Affiliation:
Experimental Rheumatology, Charité University Medicine, Berlin, Germany
Citation:
Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. 2014, 11 (1):5-16 Expert Opin Drug Deliv
Journal:
Expert opinion on drug delivery
Issue Date:
Jan-2014
URI:
http://hdl.handle.net/10033/316733
DOI:
10.1517/17425247.2013.839655
PubMed ID:
24073618
Type:
Article
Language:
en
ISSN:
1744-7593
Appears in Collections:
Publications of Dept. Gene Regulation and Differentiation (RDIF)

Full metadata record

DC FieldValue Language
dc.contributor.authorMullen, Lisaen
dc.contributor.authorRigby, Anneen
dc.contributor.authorSclanders, Michelleen
dc.contributor.authorAdams, Gillen
dc.contributor.authorMittal, Gayatrien
dc.contributor.authorColston, Juliaen
dc.contributor.authorFatah, Rewasen
dc.contributor.authorSubang, Cristinaen
dc.contributor.authorFoster, Julieen
dc.contributor.authorFrancis-West, Philippaen
dc.contributor.authorKöster, Marioen
dc.contributor.authorHauser, Hansjörgen
dc.contributor.authorLayward, Lornaen
dc.contributor.authorVessillier, Sandrineen
dc.contributor.authorAnnenkov, Alexen
dc.contributor.authorAl-Izki, Sarahen
dc.contributor.authorPryce, Garethen
dc.contributor.authorBolton, Chrisen
dc.contributor.authorBaker, Daviden
dc.contributor.authorGould, David Jen
dc.contributor.authorChernajovsky, Yutien
dc.date.accessioned2014-05-13T08:18:00Z-
dc.date.available2014-05-13T08:18:00Z-
dc.date.issued2014-01-
dc.identifier.citationLatency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β. 2014, 11 (1):5-16 Expert Opin Drug Deliven
dc.identifier.issn1744-7593-
dc.identifier.pmid24073618-
dc.identifier.doi10.1517/17425247.2013.839655-
dc.identifier.urihttp://hdl.handle.net/10033/316733-
dc.description.abstractTargeting cytokines to sites of disease has clear advantages because it increases their therapeutic index. We designed fusion proteins of the latent-associated peptide (LAP) derived from TGF-β with various cytokines via a matrix metalloproteinase (MMP) cleavage site. This design confers latency, increased half-life and targeting to sites of inflammation. The aim of this study is to determine whether this approach can be applied to cytokines of different molecular structures and sizes.en
dc.language.isoenen
dc.rightsArchived with thanks to Expert opinion on drug deliveryen
dc.titleLatency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.en
dc.typeArticleen
dc.contributor.departmentExperimental Rheumatology, Charité University Medicine, Berlin, Germanyen
dc.identifier.journalExpert opinion on drug deliveryen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.